DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Deanxit and Rivotril in Tinnitus Patients

Information source: University Hospital, Antwerp
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Tinnitus

Intervention: Deanxit (Drug); Lactose placebo (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: University Hospital, Antwerp

Official(s) and/or principal investigator(s):
Olivier Meeus, MD, Principal Investigator, Affiliation: University Hospital, Antwerp

Summary

The purpose of this study is to investigate whether increased tinnitus reduction can be obtained with Deanxit in patients already receiving Rivotril.

Clinical Details

Official title: Additional Value of Deanxit in Tinnitus Patients Treated With Rivotril

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Visual Analogue Scale

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- pure tone, narrow band noise or polyphonic tinnitus

- unilateral or bilateral tinnitus

- VAS ≥ 4

- cochleair origin tinnitus

- tinnitus present 3 months or more

- age 18y or more

- intake Rivotril 1mg/d

- patient 'able to cooperate'

- patient able to fill in TQ en VAS

- No pontine angle pathology on MRI

Exclusion Criteria:

- pulsatile tinnitus

- pregnancy or breast feeding

- contra-indications Deanxit

- recovery myocard infarct

- conduction disorder His

- untreated glaucoma

- MAO inhibitors: 15d stop

- otosclerosis

- middle ear pathologies

- Ménière

- somatic tinnitus

Locations and Contacts

Antwerp University Hospital, Antwerp 2650, Belgium
Additional Information

Starting date: February 2009
Last updated: August 10, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017